Sara Olivotto

Sara Olivotto

Auto-generated profile, based on publicly available information

Sara Olivotto

Paediatric Neurology Unit, Buzzi Children’s Hospital, Milan, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
SOSara Olivotto
Sara Olivotto
EBEleonora Basso
Eleonora Basso
RLRossella Lavatelli
Rossella Lavatelli
RPRoberto Previtali
Roberto Previtali
LPLaura Parenti
Laura Parenti
SBStefania Maria Bova
Stefania Maria Bova

1 January 2022 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
SMSilvia Masnada
Silvia Masnada
CSCatherine Sarret
Catherine Sarret
CAClara Eleonora Antonello
Clara Eleonora Antonello
AFAla Fadilah
Ala Fadilah
HKHeiko Krude
Heiko Krude
DTDavide Tonduti
Davide Tonduti

Verified
Journal Article
Open access
PDF file
AMAlessia Mauri
Alessia Mauri
ADAlessandra Duse
Alessandra Duse
GPGiacomo Palm
Giacomo Palm
RPRoberto Previtali
Roberto Previtali
SBStefania Maria Bova
Stefania Maria Bova
CCCristina Cereda
Cristina Cereda
GLUT1 deficiency syndrome (GLUT1DS1; OMIM #606777) is a rare genetic metabolic disease, characterized by infantile-onset epileptic encephalopathy, global developmental delay, progressive microcephaly, and movement disorders (e.g., spasticity and dystonia). It is caused by heterozygous mutations in the SLC2A1 gene, which encodes the GLUT1 protein, a glucose transporter across the blood-brain barrier (BBB). Most commonly, these variants arise de novo resulting in sporadic cases, although several familial cases with AD inheritance pattern have been described. Twenty-seven Italian pediatric patients, clinically suspect of GLUT1DS from both sporadic and familial cases, have been enrolled. We detected by trios sequencing analysis 25 different variants causing GLUT1DS. Of these, 40% of the identified variants (10 out of 25) had never been reported before, including missense, frameshift, and splice site variants. Their structural mapping on the X-ray structure of GLUT1 strongly suggested the potential pathogenic effects of these novel disease-related mutations, broadening the genotypic spectrum heterogeneity found in the SLC2A1 gene. Moreover, 24% is located in a vulnerable region of the GLUT1 protein that involves transmembrane 4 and 5 helices encoded by exon 4, confirming a mutational hotspot in the SLC2A1 gene. Lastly, we investigated possible correlations between mutation type and clinical and biochemical data observed in our GLUT1DS cohort, revealing that splice site and frameshift variants are related to a more severe phenotype and low CSF parameters.

10 September 2024 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
EDEnza D'auria
Enza D'auria
SBStefania Maria Bova
Stefania Maria Bova
ADAndrea Riccardo Dallapiccola
Andrea Riccardo Dallapiccola
RSRaffaella De Santis
Raffaella De Santis
ALAlessandro Leone
Alessandro Leone
Gianvincenzo ZuccottiGianvincenzo Zuccotti
Gianvincenzo Zuccotti
Multisystem inflammatory syndrome is a severe complication of SARS-CoV-2 infection in children (MIS-C). To date, data on long-term sequelae mainly concern cardiac outcomes. All ≤ 18 year olds consecutively admitted to the Buzzi Children’s Hospital with a diagnosis of MIS-C between October 1, 2020, and May 31, 2022, were followed up for up to 12 months by a dedicated multidisciplinary team. They underwent laboratory tests, multi-organ clinical and instrumental assessments, and psychosocial evaluation. 56/62 patients, 40 M, mean age 8.7 years (95% CI 7.7, 9.7), completed the follow-up. Cardiological, gastroenterological, pneumological, and neurological evaluations, including IQ and EEG, were normal. Alterations of HOMA-IR index and/or TyG index, observed in almost all patients during hospitalisation, persisted in about a third of the population at 12 months. At 6 and 12 months respectively, impairment of adaptive functions was observed in 38/56 patients (67.9%) and 25/56 (44.6%), emotional and behavioural problems in 10/56 (17.9%) and 9/56 (16.1%), and decline in QoL in 14/56 (25.0%) and 9/56 (16.1%). Psychosocial well-being impairment was significantly more frequent in the subgroup with persistent glycometabolic dysfunction at 12 months (75% vs. 40.9% p < 0.001).Conlusion: The mechanisms that might explain the long-term persistence of both metabolic alterations and neuro-behavioural outcomes and their possible relationship are far from being clarified. Our study points out to the potential long-term effects of pandemics and to the importance of a multidisciplinary follow-up to detect potential negative sequelae in different areas of health, both physical and psychosocial. What is known:• Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection.• Few data exist on the medium- and long-term outcomes of MIS-C, mostly focused on cardiac involvement. Emerging evidence shows neurological and psychological sequelae at mid- and long-term follow-up. What is new:• This study reveals that MIS-C may lead to long-term glycometabolic dysfunctions joined to impairment in the realm of general well-being and decline in quality of life, in a subgroup of children.• This study highlights the importance of a long-term multidisciplinary follow-up of children hospitalised with MIS-C, in order to detect the potential long-term sequelae in different areas of health, both physical and psychosocial well-being.

5 June 2024 in Pediatric Neurology
Verified
Journal Article
Open access
SOSara Olivotto
Sara Olivotto
AFAnna Freddi
Anna Freddi
RPRoberto Previtali
Roberto Previtali
AMAlessia Mauri
Alessia Mauri
CCCristina Cereda
Cristina Cereda
PVPierangelo Veggiotti
Pierangelo Veggiotti
Since the initial description of glucose transporter-1 deficiency syndrome (Glut1-DS) the phenotype of the condition has expanded, even leading to the recognition of atypical manifestations. We report on eight patients with Glut1-DS who experienced at least one episode of acute focal neurological deficits. We conducted a retrospective analysis, collecting clinical, electrophysiological, neuroradiological, and genetic information. We focused in particular on three well-documented cases. Among 42 patients with Glut1-DS, eight individuals aged between six and 38 years presented with an acute onset of neurological disturbances: dysarthria/aphasia, oral dyskinesia, swallowing difficulties, paresthesia, facial palsy, hemi/monoplegia, vomiting, headache, and behavioral disturbances. When performed, magnetic resonance imaging (MRI) revealed signs of venous congestion and hypoperfusion and electroencephalography showed focal contralateral slowing. Deficits were transient in all patients but one. Four patients (50%) were on a ketogenic diet (KD), and two of these patients had lower than usual ketonemia levels during the episode. In two patients, MRI demonstrated the presence of an ischemic brain lesion. In Glut1-DS, stroke-like episodes are a recurrent manifestation, particularly during early adulthood, and they were reported in 19% of the patients in our cohort. Stroke mimics should be considered a key feature of Glut1-DS, as other paroxysmal disorders. It remains to be established whether a KD can prevent the recurrence of episodes and, if so, at what level of ketosis. Further observations are needed to confirm the correlation between Glut1-DS and ischemic stroke.

20 April 2022 in Epilepsy & Behavior Reports
Verified
Journal Article
Open access
SOSara Olivotto
Sara Olivotto
AFAnna Freddi
Anna Freddi
RLRossella Lavatelli
Rossella Lavatelli
EBEleonora Basso
Eleonora Basso
ALAlessia Leidi
Alessia Leidi
PVPierangelo Veggiotti
Pierangelo Veggiotti
• Generalized epilepsies with variants in GABRA1 may be a treatment challenge when myoclonus remains drug-resistant. • Photosensitivity may be particularly disabling and is without feature-specific treatments. • We describe an adolescent with GABRA1 mutation and photosensitivity who improved with PER.